SAXAGEN-M 500 SR Tablets

Next Generation Anti-diabetic

COMPOSITION – Saxagliptin 5 mg + Metformin HCI 500 mg ER (Extended Release) 




  • Drug class: Dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Weight neutral with low risk of hypoglycemia.
  • Demonstrates a statistically significant and clinically meaningful improvement in glycemic control.
  • More efficacious and have a better safety profile than acarbose and sulfonylurea.
  • Efficiently lowers FPG (fasting plasma glucose) and PPG (Postprandial glucose levels in combination therapy with metformin.


  • Drug class: Biguanides 

Metformin HCI

  • Excellent hyperglycaemic agent lowers blood sugar levels without causing hypoglycemia.
  • Effectual in the treatment of Type 2 diabetes mellitus, Gestational diabetes, and non-insulin-dependent diabetes mellitus in obese patients.
  • Its sustained release mechanism reduces adverse effects and improves medication adherence.
  • Improves endothelial oxidative stress levels, and insulin sensitivity and attenuates hyperglycemia-induced inflammation.

Saxagliptin (SAXA)/metformin (MET) Fixed-dose combination (FDC) 2.5/500 mg

  • SAXA/MET FDC is a patient-friendly, dosage-flexible, and hypoglycemia-safe with very few adverse events and a neutral or even favorable effect on body weight.
  • It achieves significant glycosylated hemoglobin A1c reduction helping the patient to achieve his/her individual glycemic goals.
  • SAXA/MET FDC represents a good choice for amplifying patients’ compliance and adherence to the therapeutic regimen.


Saxagliptin 5 mg + Metformin HCI 500 mg ER (Extended Release)


  • To treat high blood sugar (glucose) levels in patients with type 2 diabetes.